Market Overview

UPDATE: Goldman Sachs Reiterates Sell Rating, $62 PT on Humana

Related HUM
Tenet Healthcare Extends Contract with Humana to Drive Growth
Humana Touches New 52-Week High on Favorable Developments - Analyst Blog
Humana Sees Exchange Customer Growth in '14 (Fox Business)

In a report published Wednesday, Goldman Sachs Group reiterated its Sell rating and $62.00 price target on Humana (NYSE: HUM).

Goldman Sachs noted, “The focus of the investor day was the transition to provider-integrated care (owned and risk-contracted) that offers lower cost / higher quality outcomes versus traditional fee-for-service. With Medicare Advantage (MA) driving the majority of revenue and earnings, we think integrated care is the right model to better position Humana for tighter MA reimbursement as health reform rolls through and also the right model to strengthen Humana's role in easing the national Medicare cost crisis in the years ahead.”

Humana closed on Tuesday at $68.29.

Posted-In: Goldman Sachs GroupAnalyst Color Reiteration Analyst Ratings

 

Most Popular

Related Articles (HUM)

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free